Redeye: Medivir (Q3 Review) - New Phase II Study
7 november, 2025
7 november, 2025
Redeye comments on Medivir’s Q2 report. A rights issue of cSEK150m was announced, which will fund a new investigator-sponsored trial, smaller than previously but with a control arm. Remetinostat was outlicensed to Biossil for up to USD60m in milestones, a limited deal. We update our base case.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/
Attachments
7 november, 2025
Redeye comments on Medivir’s Q2 report. A rights issue of cSEK150m was announced, which will fund a new investigator-sponsored trial, smaller than previously but with a control arm. Remetinostat was outlicensed to Biossil for up to USD60m in milestones, a limited deal. We update our base case.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/
Attachments
Flat Capital
Nya bolåneregler
Analys
Fonder

ETF:er
Flat Capital
Nya bolåneregler
Analys
Fonder

ETF:er
1 DAG %
Senast
OMX Stockholm 30
−1,35%
(vid stängning)
OMX Stockholm 30
1 DAG %
Senast
2 965,69